Literature DB >> 27799566

Epigenetic gene regulation by Janus kinase 1 in diffuse large B-cell lymphoma.

Lixin Rui1,2,3, Amanda C Drennan2,3, Michele Ceribelli4, Fen Zhu2,3, George W Wright5, Da Wei Huang4, Wenming Xiao6, Yangguang Li2,3, Kreg M Grindle2,3, Li Lu2,3, Daniel J Hodson4, Arthur L Shaffer4, Hong Zhao4, Weihong Xu4, Yandan Yang4, Louis M Staudt1.   

Abstract

Janus kinases (JAKs) classically signal by activating STAT transcription factors but can also regulate gene expression by epigenetically phosphorylating histone H3 on tyrosine 41 (H3Y41-P). In diffuse large B-cell lymphomas (DLBCLs), JAK signaling is a feature of the activated B-cell (ABC) subtype and is triggered by autocrine production of IL-6 and IL-10. Whether this signaling involves STAT activation, epigenetic modification of chromatin, or both mechanisms is unknown. Here we use genetic and pharmacological inhibition to show that JAK1 signaling sustains the survival of ABC DLBCL cells. Whereas STAT3 contributed to the survival of ABC DLBCL cell lines, forced STAT3 activity could not protect these cells from death following JAK1 inhibition, suggesting epigenetic JAK1 action. JAK1 regulated the expression of nearly 3,000 genes in ABC DLBCL cells, and the chromatin surrounding many of these genes was modified by H3Y41-P marks that were diminished by JAK1 inhibition. These JAK1 epigenetic target genes encode important regulators of ABC DLBCL proliferation and survival, including IRF4, MYD88, and MYC. A small molecule JAK1 inhibitor cooperated with the BTK inhibitor ibrutinib in reducing IRF4 levels and acted synergistically to kill ABC DLBCL cells, suggesting that this combination should be evaluated in clinical trials.

Entities:  

Keywords:  JAK1; epigenetics; histone modification; lymphoma; oncogene

Mesh:

Substances:

Year:  2016        PMID: 27799566      PMCID: PMC5135360          DOI: 10.1073/pnas.1610970113

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  40 in total

1.  Oncogenically active MYD88 mutations in human lymphoma.

Authors:  Vu N Ngo; Ryan M Young; Roland Schmitz; Sameer Jhavar; Wenming Xiao; Kian-Huat Lim; Holger Kohlhammer; Weihong Xu; Yandan Yang; Hong Zhao; Arthur L Shaffer; Paul Romesser; George Wright; John Powell; Andreas Rosenwald; Hans Konrad Muller-Hermelink; German Ott; Randy D Gascoyne; Joseph M Connors; Lisa M Rimsza; Elias Campo; Elaine S Jaffe; Jan Delabie; Erlend B Smeland; Richard I Fisher; Rita M Braziel; Raymond R Tubbs; J R Cook; Denny D Weisenburger; Wing C Chan; Louis M Staudt
Journal:  Nature       Date:  2010-12-22       Impact factor: 49.962

2.  Oncogenic CARD11 mutations in human diffuse large B cell lymphoma.

Authors:  Georg Lenz; R Eric Davis; Vu N Ngo; Lloyd Lam; Thaddeus C George; George W Wright; Sandeep S Dave; Hong Zhao; Weihong Xu; Andreas Rosenwald; German Ott; Hans Konrad Muller-Hermelink; Randy D Gascoyne; Joseph M Connors; Lisa M Rimsza; Elias Campo; Elaine S Jaffe; Jan Delabie; Erlend B Smeland; Richard I Fisher; Wing C Chan; Louis M Staudt
Journal:  Science       Date:  2008-03-06       Impact factor: 47.728

3.  Cooperative epigenetic modulation by cancer amplicon genes.

Authors:  Lixin Rui; N C Tolga Emre; Michael J Kruhlak; Hye-Jung Chung; Christian Steidl; Graham Slack; George W Wright; Georg Lenz; Vu N Ngo; Arthur L Shaffer; Weihong Xu; Hong Zhao; Yandan Yang; Laurence Lamy; R Eric Davis; Wenming Xiao; John Powell; David Maloney; Craig J Thomas; Peter Möller; Andreas Rosenwald; German Ott; Hans Konrad Muller-Hermelink; Kerry Savage; Joseph M Connors; Lisa M Rimsza; Elias Campo; Elaine S Jaffe; Jan Delabie; Erlend B Smeland; Dennis D Weisenburger; Wing C Chan; Randy D Gascoyne; David Levens; Louis M Staudt
Journal:  Cancer Cell       Date:  2010-12-14       Impact factor: 31.743

4.  Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma.

Authors:  Wyndham H Wilson; Ryan M Young; Roland Schmitz; Yandan Yang; Stefania Pittaluga; George Wright; Chih-Jian Lih; P Mickey Williams; Arthur L Shaffer; John Gerecitano; Sven de Vos; Andre Goy; Vaishalee P Kenkre; Paul M Barr; Kristie A Blum; Andrei Shustov; Ranjana Advani; Nathan H Fowler; Julie M Vose; Rebecca L Elstrom; Thomas M Habermann; Jacqueline C Barrientos; Jesse McGreivy; Maria Fardis; Betty Y Chang; Fong Clow; Brian Munneke; Davina Moussa; Darrin M Beaupre; Louis M Staudt
Journal:  Nat Med       Date:  2015-07-20       Impact factor: 53.440

5.  The JAK2 inhibitor AZD1480 potently blocks Stat3 signaling and oncogenesis in solid tumors.

Authors:  Michael Hedvat; Dennis Huszar; Andreas Herrmann; Joseph M Gozgit; Anne Schroeder; Adam Sheehy; Ralf Buettner; David Proia; Claudia M Kowolik; Hong Xin; Brian Armstrong; Geraldine Bebernitz; Shaobu Weng; Lin Wang; Minwei Ye; Kristen McEachern; Huawei Chen; Deborah Morosini; Kirsten Bell; Marat Alimzhanov; Stephanos Ioannidis; Patricia McCoon; Zhu A Cao; Hua Yu; Richard Jove; Michael Zinda
Journal:  Cancer Cell       Date:  2009-12-08       Impact factor: 31.743

6.  Drosophila STAT is required for directly maintaining HP1 localization and heterochromatin stability.

Authors:  Song Shi; Kimberly Larson; Dongdong Guo; Su Jun Lim; Pranabananda Dutta; Shian-Jang Yan; Willis X Li
Journal:  Nat Cell Biol       Date:  2008-03-16       Impact factor: 28.824

7.  CARMA1- and MyD88-dependent activation of Jun/ATF-type AP-1 complexes is a hallmark of ABC diffuse large B-cell lymphomas.

Authors:  Mélanie Juilland; Montserrat Gonzalez; Tabea Erdmann; Yara Banz; Zala Jevnikar; Stephan Hailfinger; Alexandar Tzankov; Michael Grau; Georg Lenz; Urban Novak; Margot Thome
Journal:  Blood       Date:  2016-01-08       Impact factor: 22.113

8.  Targeting sphingosine kinase induces apoptosis and tumor regression for KSHV-associated primary effusion lymphoma.

Authors:  Zhiqiang Qin; Lu Dai; Jimena Trillo-Tinoco; Can Senkal; Wenxue Wang; Tom Reske; Karlie Bonstaff; Luis Del Valle; Paulo Rodriguez; Erik Flemington; Christina Voelkel-Johnson; Charles D Smith; Besim Ogretmen; Chris Parsons
Journal:  Mol Cancer Ther       Date:  2013-10-18       Impact factor: 6.261

9.  Constitutively activated Stat3 protects fibroblasts from serum withdrawal and UV-induced apoptosis and antagonizes the proapoptotic effects of activated Stat1.

Authors:  Y Shen; G Devgan; J E Darnell; J F Bromberg
Journal:  Proc Natl Acad Sci U S A       Date:  2001-02-06       Impact factor: 11.205

10.  Constitutive nuclear factor kappaB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells.

Authors:  R E Davis; K D Brown; U Siebenlist; L M Staudt
Journal:  J Exp Med       Date:  2001-12-17       Impact factor: 14.307

View more
  24 in total

Review 1.  HiJAKing the epigenome in leukemia and lymphoma.

Authors:  Amanda C Drennan; Lixin Rui
Journal:  Leuk Lymphoma       Date:  2017-04-12

2.  Parsaclisib, a potent and highly selective PI3Kδ inhibitor, in patients with relapsed or refractory B-cell malignancies.

Authors:  Andres Forero-Torres; Radhakrishnan Ramchandren; Abdulraheem Yacoub; Michael S Wertheim; William J Edenfield; Paolo Caimi; Martin Gutierrez; Luke Akard; Carolina Escobar; Justin Call; Daniel Persky; Swaminathan Iyer; Douglas J DeMarini; Li Zhou; Xuejun Chen; Fitzroy Dawkins; Tycel J Phillips
Journal:  Blood       Date:  2019-02-25       Impact factor: 22.113

Review 3.  Pathogenic B-cell receptor signaling in lymphoid malignancies: New insights to improve treatment.

Authors:  Ryan M Young; James D Phelan; Wyndham H Wilson; Louis M Staudt
Journal:  Immunol Rev       Date:  2019-09       Impact factor: 12.988

Review 4.  JAK/STAT signaling in stem cells and regeneration: from Drosophila to vertebrates.

Authors:  Salvador C Herrera; Erika A Bach
Journal:  Development       Date:  2019-01-29       Impact factor: 6.868

5.  Gene regulation and suppression of type I interferon signaling by STAT3 in diffuse large B cell lymphoma.

Authors:  Li Lu; Fen Zhu; Meili Zhang; Yangguang Li; Amanda C Drennan; Shuichi Kimpara; Ian Rumball; Christopher Selzer; Hunter Cameron; Ashley Kellicut; Amanda Kelm; Fangyu Wang; Thomas A Waldmann; Lixin Rui
Journal:  Proc Natl Acad Sci U S A       Date:  2018-01-02       Impact factor: 11.205

6.  Specific covalent inhibition of MALT1 paracaspase suppresses B cell lymphoma growth.

Authors:  Lorena Fontán; Qi Qiao; John M Hatcher; Gabriella Casalena; Ilkay Us; Matt Teater; Matt Durant; Guangyan Du; Min Xia; Natalia Bilchuk; Spandan Chennamadhavuni; Giuseppe Palladino; Giorgio Inghirami; Ulrike Philippar; Hao Wu; David A Scott; Nathanael S Gray; Ari Melnick
Journal:  J Clin Invest       Date:  2018-07-19       Impact factor: 14.808

7.  An oncogenic axis of STAT-mediated BATF3 upregulation causing MYC activity in classical Hodgkin lymphoma and anaplastic large cell lymphoma.

Authors:  A Lollies; S Hartmann; M Schneider; T Bracht; A L Weiß; J Arnolds; L Klein-Hitpass; B Sitek; M-L Hansmann; R Küppers; M A Weniger
Journal:  Leukemia       Date:  2017-06-29       Impact factor: 11.528

8.  Nuclear Import of JAK1 Is Mediated by a Classical NLS and Is Required for Survival of Diffuse Large B-cell Lymphoma.

Authors:  Fen Zhu; Byounghoon Hwang; Shigeki Miyamoto; Lixin Rui
Journal:  Mol Cancer Res       Date:  2016-12-28       Impact factor: 5.852

9.  IL-6/JAK1 pathway drives PD-L1 Y112 phosphorylation to promote cancer immune evasion.

Authors:  Li-Chuan Chan; Chia-Wei Li; Weiya Xia; Jung-Mao Hsu; Heng-Huan Lee; Jong-Ho Cha; Hung-Ling Wang; Wen-Hao Yang; Er-Yen Yen; Wei-Chao Chang; Zhengyu Zha; Seung-Oe Lim; Yun-Ju Lai; Chunxiao Liu; Jielin Liu; Qiongzhu Dong; Yi Yang; Linlin Sun; Yongkun Wei; Lei Nie; Jennifer L Hsu; Hui Li; Qinghai Ye; Manal M Hassan; Hesham M Amin; Ahmed O Kaseb; Xin Lin; Shao-Chun Wang; Mien-Chie Hung
Journal:  J Clin Invest       Date:  2019-07-15       Impact factor: 14.808

10.  Targeting phosphatidylinositol 3 kinase-β and -δ for Bruton tyrosine kinase resistance in diffuse large B-cell lymphoma.

Authors:  Neeraj Jain; Satishkumar Singh; Georgios Laliotis; Amber Hart; Elizabeth Muhowski; Kristyna Kupcova; Tereza Chrbolkova; Tamer Khashab; Sayan Mullick Chowdhury; Anuvrat Sircar; Fazal Shirazi; Ram Kumar Singh; Lapo Alinari; Jiangjiang Zhu; Ondrej Havranek; Philip Tsichlis; Jennifer Woyach; Robert Baiocchi; Felipe Samaniego; Lalit Sehgal
Journal:  Blood Adv       Date:  2020-09-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.